Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy

The aim of this study was to investigate the potential of progesterone receptor (PgR) as a biomarker for differentiating estrogen receptor (ER)-positive patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy (NCT) with different prognoses. A total of 327 consecutiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Sheng, Huang, Liang, Chen, Can-Ming, Shao, Zhi-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627243/
https://www.ncbi.nlm.nih.gov/pubmed/26053183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627243/
https://www.ncbi.nlm.nih.gov/pubmed/26053183

Ejemplares similares